Life Sciences

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26 October 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies

Read the press release
Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products
2 November 2016

Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, announced today that the...

Read the press release
TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
4 December 2014

TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse